IMMUNOHISTOCHEMISTRY BRAF V600E Test at DNA Labs UAE
The IMMUNOHISTOCHEMISTRY BRAF V600E test is an important diagnostic tool used in the detection of a specific mutation in the BRAF gene known as V600E. This mutation is commonly found in various cancers, including melanoma, colorectal cancer, and thyroid cancer.
Test Details
The IMMUNOHISTOCHEMISTRY BRAF V600E test is conducted using immunohistochemistry (IHC) techniques. It involves staining tissue samples with an antibody that specifically targets the BRAF V600E mutation. If the mutation is present, the antibody will bind to the mutated protein, resulting in a visible signal, typically a color change.
Test Components and Cost
The IMMUNOHISTOCHEMISTRY BRAF V600E test is priced at 590.0 AED. The test requires a tumor tissue sample submitted in 10% Formal-saline or a Formalin-fixed paraffin-embedded block. The sample should be shipped at room temperature. Additionally, a copy of the Histopathology report, the site of biopsy, and the patient’s clinical history should be provided.
Report Delivery
The report for the IMMUNOHISTOCHEMISTRY BRAF V600E test is delivered on a daily basis by 6 pm. The delivery time varies depending on the type of sample: 5 days for a report on a block, 5 days for a tissue biopsy report, and 7 days for a report on a large complex tissue.
Method and Test Type
The IMMUNOHISTOCHEMISTRY BRAF V600E test is conducted using the immunohistochemistry method. It is categorized as a cancer test and is typically requested by an oncologist. The test is performed in the Histology department of DNA Labs UAE.
Pre Test Information
Prior to conducting the IMMUNOHISTOCHEMISTRY BRAF V600E test, it is necessary to provide a copy of the Histopathology report, the site of biopsy, and the patient’s clinical history. This information aids in the accurate interpretation of the test results.
Significance and Treatment Implications
The presence of the BRAF V600E mutation in cancer cells has significant implications for prognosis and treatment planning. Certain targeted therapies, such as BRAF inhibitors, have been developed specifically to target tumors with this mutation. The IMMUNOHISTOCHEMISTRY BRAF V600E test plays a crucial role in identifying the presence of this mutation, guiding treatment decisions, and improving patient outcomes.
Overall, the IMMUNOHISTOCHEMISTRY BRAF V600E test conducted at DNA Labs UAE is a valuable tool in cancer diagnosis and treatment planning. It helps in detecting the specific mutation and enables personalized treatment options for patients.
| Test Name | IMMUNOHISTOCHEMISTRY BRAF V600E Test |
|---|---|
| Components | |
| Price | 590.0 AED |
| Sample Condition | Submit tumor tissue in 10% Formal-saline OR Formalin fixed paraffin embedded block. Ship at room temperature. Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Report Delivery | Sample Daily by 6 pm; Report Block: 5 days Tissue Biopsy: 5 days Tissue large complex : 7 days |
| Method | Immunohistochemistry |
| Test type | Cancer |
| Doctor | Oncologist |
| Test Department: | HISTOLOGY |
| Pre Test Information | Provide a copy of the Histopathology report, Site of biopsy and Clinical history. |
| Test Details | The BRAF V600E test is a type of immunohistochemistry (IHC) test used to detect a specific mutation in the BRAF gene called V600E. This mutation is commonly found in various cancers, including melanoma, colorectal cancer, and thyroid cancer. Immunohistochemistry is a technique that uses antibodies to detect specific proteins in tissue samples. In the case of the BRAF V600E test, the tissue sample is typically obtained from a biopsy or surgical resection of the tumor. The test involves staining the tissue sample with an antibody that specifically targets the BRAF V600E mutation. If the mutation is present, the antibody will bind to the mutated protein and produce a visible signal, usually in the form of a color change. This allows pathologists to identify whether the BRAF V600E mutation is present in the tumor cells. The BRAF V600E test is important in cancer diagnosis and treatment planning. The presence of this mutation can have implications for prognosis and treatment options. For example, certain targeted therapies, such as BRAF inhibitors, have been developed specifically to target tumors with the BRAF V600E mutation. Overall, the immunohistochemistry BRAF V600E test is a valuable tool in identifying the presence of this specific mutation in cancer cells and guiding treatment decisions for patients. |
